Clearmind Medicine Inc

Clearmind Medicine’s CMND‑100 shows a strong safety profile and partners with Polyrizon for intranasal CNS therapy, boosting investor confidence and clinical momentum.

Clearmind’s CMND‑100 AUD trial gains Hadassah approval, boosting recruitment, data quality, and investor confidence in its non‑hallucinogenic MEAI therapy.

Clearmind Medicine’s new MEAI patent and first‑cohort AUD data show breakthrough neuro‑plasticity treatments for cocaine and alcohol addiction, boosting investor and clinical interest.

Clearmind Medicine Inc. has achieved a major milestone in its efforts to combat Alcohol Use Disorder (AUD) with the successful dosing of its innovative CMND-100 treatment in a Phase I/IIa clinical trial.